Antimicrobial resistance: Cost and Containtment

Expert Review of Anti-Infective Therapy

Volumn 1, Issue 2, 2003, Pages 241-251

  Coast, Joanna ^a   Smith, Richard D ^b  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

Antimicrobial resistance; Containment; Costs; Economics

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BACTERIAL VACCINE; METICILLIN; PROBIOTIC AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; BACTERIAL INFECTION; BACTERIAL TRANSMISSION; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; DIAGNOSTIC TEST; DRUG COST; ECONOMIC EVALUATION; ERADICATION THERAPY; HAND WASHING; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HEALTH SURVEY; HOSPITAL INFECTION; HUMAN; INFECTION CONTROL; INFECTION SENSITIVITY; MEDICAL DECISION MAKING; MEDICAL INFORMATION; MEDICAL LITERATURE; MEDICAL RESEARCH; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHODOLOGY; NONBIOLOGICAL MODEL; NONHUMAN; NUTRITIONAL HEALTH; PATIENT COMPLIANCE; REVIEW; SALMONELLA; SCREENING TEST; SOCIOECONOMICS; TREATMENT PLANNING; URINARY TRACT INFECTION; VACCINATION;

EID: 3042824855     PISSN: 14787210     EISSN: None     Source Type: Journal    
DOI: 10.1586/14787210.1.2.241     Document Type: Review

References (45)

1. Ashley DJB, Brindle MJ. Penicillin resistance in staphylococci isolated in a casualty department. J. Clin. Pathol. 13, 336-338 (1960).
2. Standing Medical Advisory Committee Sub-Group on Antimicrobial Resistance. The path of least resistance. Department of Health, London, UK, (1998).
3. Magee JT, Pritchard EL, Fitzgerald KA, Dunstan FDJ, Howard AJ, Welsh Antibiotic Study Group. Antibiotic prescribing and antibiotic resistance in community practice: retrospective study, 1996-1998. Br. Med. J. 319, 1239-1240 (1999).
4. Coast J, Smith RD, Millar MR. Superbugs: should antimicrobial resistance be included as a cost in economic evaluation? Health Econ. 5, 217-226 (1996).
5. World Health Organisation. Overcoming antimicrobial resistance, WHO/CDS/2000.2. WHO, Geneva, Switzerland, (2000).
6. Tan TY, McNulty C, Charlett A, Nessa N, Kelly C, Beswick T. Laboratory antibiotic susceptibility reporting and antibiotic prescribing in general practice. J. Antimicrob. Chemother. 51, 379-384 (2003).
7. Holmberg SD, Solomon SL, Blake PA. Health and economic impacts of antimicrobial resistance. Rev. Infect. Dis. 9(6), 1065-1078 (1987).
8. Coast J, Smith RD, Wilton P, Karcher AM, Millar MR. Superbugs II: how should economic evaluation be conducted for interventions which aim to reduce antimicrobial resistance? Health Econ. 11(7), (2002).
9. Fasehun F. The antibacterial paradox: essential drugs, effectiveness and cost. Bull. World Health Org. 77, 211-216 (1999).
10. Smith RD. Antimicrobial resistance: the importance of developing long-term policy. Bull. World Health Org. 77, 862 (1999).
11. American Society for Microbiology. Report of the ASM task force on antibiotic resistance. Antimicrob. Agents Chemoth. (Suppl.) 1-23 (1995).
12. John JF, Fishman NO. Programmatic role of the infectious diseases physician in controlling antimicrobial costs in the hospital. Clin. Infect. Dis. 24, 471-485 (1997).
13. Cox RA, Conquest C, Mallaghan C, Marples RR. A major outbreak of methicillin-resistant Staphylococcus aureus caused be a new phage-type (EMRSA-16). J. Hosp. Infect. 29, 87-106 (1995).
14. Elbasha EH. Deadweight loss of bacterial resistance due to overtreatment. Health Econ. 12, 125-138 (2003).
15. Smith RD, Coast J. Antimicrobial resistance: a global response. Bull. World Health Org.80, 126-133 (2002).
16. Levy SB. The antibiotic paradox. How miracle drugs are destroying the miracle. Plenum Press, NY, USA (1992).
17. Smith RD, Coast J, Millar MR, Wilton P, Karcher AM. Interventions against antimicrobial resistance: a review of the literature and exploration of modeling cost-effectiveness. Global Forum for Health Research, Geneva, Switzerland, (2001).
18. Drummond MF, O'Brien B, Stoddart GL, Torrance GW Methods for the economic evaluation of healthcare programmes. Oxford University Press, Oxford, UK, (1997).
19. Rudholm N. Economic implications of antibiotic resistance in a global economy. J. Health Econ. 21, 1071-1083 (2002).
20. Wilton P, Smith RD, Coast J, Millar MR. Strategies to contain the emergence of antimicrobial resistance: a systematic review of effectiveness and cost-effectiveness. J. Health Serv. Res. Pol. 7, 111-117 (2002).
21. Mulrow CD, Oxman AD. Cochrane Collaboration Handbook [updated 1st March 1997]. In: The Cochrane Library [database on disk and CDROM]. The Cochrane Collaboration. Update Software, Oxford, UK (1996).
22. Evans RS, Pestotnik SL, Burke JP. Gardner RM, Larsen RA, Classen DC. Reducing the duration of prophylactic antibiotic use through computer monitoring of surgical patients. DICP Ann. Pharmacother. 24, 351-354 (1990).
23. Climo MW, Israel DS, Wong ES, Williams D, Coudron P, Markowitz SM. Hospital-wide restriction of Clindamycin: effect on the incidence of Clostridium difficile-associated diarrhea and cost. Ann. Intern. Med. 128, 989-995 (1998).
24. Toltzsis P, Yamashita T, Vilt L, Green M, Morrissey A, Spinner-Block S et al. Antibiotic restriction does not alter endemic colonisation with resistant Gram-negative rods in a pediatric intensive care unit. Crit. Care Med. 26, 1893-1899 (1998).
25. Himmelberg CJ, Pleasants RA, Weber DJ et al. Use of antimicrobial drugs in adults before and after removal of a restriction policy. Am. J. Hosp. Pharmacists 48, 1220-1227 (1991).
26. Gonzales R, Steiner JF, Lum A, Barrett PH. Decreasing antibiotic use in ambulatory practice. Impact of a multidimensional intervention on the treatment of uncomplicated acute bronchitis in adults. J. Am. Med. Ass. 281, 1512-1519 (1999).
27. Zwar N, Wolk J, Gordon J, Sanson-Fisher R, Kehoe L. Influencing antibiotic prescribing in general practice: a trial of prescriber feedback and management guidelines. Family Practice 16, 495-500 (1999).
28. Mainous AG, Hueston WJ, Love MJ, Evans ME, Finger R. An evaluation of statewide strategies to reduce antibiotic overuse. Family Med. 32, 22-29 (2000).
29. Vakil N, Fennerty MB. Cost-effectiveness of treatment regimens for the eradication of Helicobacter pylori in duodenal ulcer. Am. J. Gastroenterol. 91, 239-245 (1996).
30. de Man P, Verhoeven BAN, Verbrugh HA, Vos MC, van den Anker JN. An antibiotic policy to prevent emergence of resistant bacilli. Lancet 355, 973-978 (2000).
31. Walsh TJ, Standiford HC, Reboli AC et al. Randomized double-blinded trial of rifampin with either novobiocin or trimethoprim sulfamethoxazole against methicillin-resistant Staphylococcus aureus colonization: prevention of antimicrobial resistance and effect of host factors on outcome. Antimicrob. Agents Chemoth. 37, 1334-1342 (1993).
32. Fine MJ, Smith MA, Carson CA. Efficacy of pneumococcal vaccination in adults: a meta-analysis of randomized controlled-trials. Archives Intern. Med. 154, 2666-2667 (1994).
33. Farr BM, Johnston L, Cobb DK et al. Preventing pneumococcal bacteremia in patients at risk. Archives Intern. Med. 155, 2336-2340 (1995).
34. Jiminez FJ, Guallar P, Rubio C. Cost-effectiveness analysis of pneumococcal vaccination in the elderly Spanish population. Br. J. Med. Econ. 10, 193-202 (1996).
35. Haley RW, Culver DH, White JW et al. The efficacy of infection surveillance and control programs in preventing nosocomial infections in US hospitals. Am. J. Epidemiol. 121, 182-205 (1985).
36. Bloom BS, Fendrick AM, Chernew ME, Patel P. Clinical and economic effects of Mupirocin Calcium on preventing Staphylococcus aureus infection in hemodialysis patients: a decision analysis. Am. J. Kidney Dis. 27, 687-694 (1996).
37. Breuer T, Graham DY. Costs of diagnosis and treatment of Helicobactor pylori infection: when does choosing the treatment regimen based on susceptibility testing become cost-effective? Am. J. Gastroenterol. 94, 725-729 (1999).
38. Verwaest C, Verhaegen J, Ferdinande P et al. Randomized, controlled trial of selective digestive decontamination in 600 mechanically ventilated patients in a multidisciplinary intensive care unit. Crit. Care Med. 25, 63-71 (1997).
39. Laxminarayan R, Brown GM. Economics of antibiotic resistance: a theory of optimal use. J. Env. Econ. Manag. 42, 183-206 (2001).
40. Rowthorn R, Brown GM. Using antibiotics when resistance is renewable. In Laxminarayan R, ed. Battling Resistance to Antibiotics and Pesticides. An Economic Approach. Resources for the Future, DC, USA (2003).
41. Wilen JE, Msangi S. Dynamics of antibiotic use. Ecological versus interventionist strategies to manage resistance to antibiotics. In: Battling Resistance to Antibiotics and Pesticides. an Economic Approach. Laxminarayan R (Ed.), 17-41. Resources for the Future, DC, USA, (2003).
42. Sanchirico JN. To take or not to take the antibiotic? In: Battling Resistance to Antibiotics and Pesticides. An Economic Approach,. Resources for the Future, DC, USA, 76-83 (2003).
43. World Health Organisation. Global strategy for the containment of antimicrobial resistance. WHO/CDS/CSR/DRS/2001.2. World Health Organisation, Geneva, Switzerland, (2001).
44. Coast J, Smith RD, Millar MR. An economic perspective on policy to reduce antimicrobial resistance. Social Sci. Med. 46(1), 29-38 (1998).
45. Levy SB. The Antibiotic Paradox. Perseus Publishing, MA, USA, (2002).